Disabling Abl - Perspectives on Abl kinase regulation and cancer therapeutics

被引：47

作者：

Sawyers, CL ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Med, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Urol, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Mol Pharmacol, Los Angeles, CA 90095 USA

来源：

CANCER CELL | 2002年 / 1卷 / 01期

关键词：

D O I：

10.1016/S1535-6108(02)00022-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pharmacologic inhibition of the Bcr-Abl tyrosine kinase in human chronic myeloid leukemia leads to dramatic clinical responses, but relapses occur in advanced stage patients. New findings about Abl kinase domain regulation provide insight into novel strategies for targeted therapy.

引用

页码：13 / 15

页数：3

共 17 条

[1] An intramolecular SH3-domain interaction regulates c-Abl activity
Barilá, D
Superti-Furga, G
[J]. NATURE GENETICS, 1998, 18 (03) : 280 - 282
[2] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS
BUCHDUNGER, E
ZIMMERMANN, J
METT, H
MEYER, T
MULLER, M
REGENASS, U
LYDON, NB
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) : 2558 - 2562
[3] The tyrosine kinase Abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13):: Molecular cloning of both reciprocal transcripts
Cazzaniga, G
Tosi, S
Aloisi, A
Giudici, G
Daniotti, M
Pioltelli, P
Kearney, L
Biondi, A
[J]. BLOOD, 1999, 94 (12) : 4370 - 4373
[4] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042
[5] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, BJ
Tamura, S
Buchdunger, E
Ohno, S
Segal, GM
Fanning, S
Zimmermann, J
Lydon, NB
[J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
[6] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
[7] Golub TR, 1996, MOL CELL BIOL, V16, P4107
[8] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Gorre, ME
Mohammed, M
Ellwood, K
Hsu, N
Paquette, R
Rao, PN
Sawyers, CL
[J]. SCIENCE, 2001, 293 (5531) : 876 - 880
[9] Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y
Bishop, A
Witucki, L
Kraybill, B
Shimizu, E
Tsien, J
Ubersax, J
Blethrow, J
Morgan, DO
Shokat, KM
[J]. CHEMISTRY & BIOLOGY, 1999, 6 (09): : 671 - 678
[10] PAPADOPOULOS P, 1995, CANCER RES, V55, P34

← 1 2 →